AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29961572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (280 mg intravenous infusion)
Number of subjects: 117
Study 29961572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 28801444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical maintenance BCG (mBCG) immunotherapy
Number of subjects: 60
Study 28801444 — intervention group
Group type: COMPARATOR
Intervention: Primary radical cystectomy (RC)
Number of subjects: 60
Study 23463301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tränkmann's bite-jumping appliances
Number of subjects: 69
Study 23463301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 21576829 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (40-80 mg)
Number of subjects: 191
Study 21576829 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 191
Study 19225814 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 32
Study 19225814 — intervention group
Group type: COMPARATOR
Intervention: Panavia F 2.0
Number of subjects: 32
Study 19225814 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem
Number of subjects: 32
Study 19225814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink Sprint
Number of subjects: 32
Study 16786354 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 18
Study 16786354 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 18
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg x kg(‐1) 0.5% levobupivacaine
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg x kg(‐1) levobupivacaine
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg x kg(‐1) levobupivacaine
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) levobupivacaine
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean duration of lower limb motor blockade
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor block MLAD
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: ED50
Number of subjects: 50
Study 15385012 — intervention group
Group type: EXPERIMENTAL
Intervention: ED95
Number of subjects: 50
Study 11203270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-tablets (filled into hard gelatin capsules)
Number of subjects: 8
Study 11203270 — intervention group
Group type: COMPARATOR
Intervention: Commercial matrix formulation (Ibu-Slow 600)
Number of subjects: 8
Study 9363358 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor thresholds measured at 04:00 h and 16:00 h
Number of subjects: 5
Study 9363358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal pain thresholds measured at 04:00 h and 16:00 h
Number of subjects: 5
Study 1778222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion
Number of subjects: 21
Study 1778222 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous glucose infusion [44.4 mumol kg‐1 body weight (bw) min‐1]
Number of subjects: 21
Study 7130741 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational liquid formula of 8-methoxypsoralen
Number of subjects: 0
Study 7130741 — intervention group
Group type: COMPARATOR
Intervention: Conventional crystalline 8-methoxypsoralen
Number of subjects: 0
Study 30817696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 20
Study 30817696 — intervention group
Group type: COMPARATOR
Intervention: Well Rested
Number of subjects: 20
Study 28414806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care (comprehensive geriatric assessment and tailored interventions)
Number of subjects: 2283
Study 28414806 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2283
Study 28414806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care
Number of subjects: 2283
Study 27220987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS)
Number of subjects: 0
Study 27220987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACS)
Number of subjects: 0
Study 27220987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (ACS exposure)
Number of subjects: 0
Study 27220987 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS administration within 7 days of delivery
Number of subjects: 0
Study 23904492 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward expected and received
Number of subjects: 0
Study 23904492 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward expected but not received
Number of subjects: 0
Study 23904492 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward not expected and not received
Number of subjects: 0
Study 23904492 — intervention group
Group type: COMPARATOR
Intervention: Dopaminergic modulation (L-DOPA)
Number of subjects: 0
Study 21757054 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (84/7 days)
Number of subjects: 1315
Study 21757054 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (21/7 days)
Number of subjects: 1315
Study 17293790 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50
Study 17293790 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study 16309769 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-radiation with 18 Gy at 1 mm vessel depth (n = 53)
Number of subjects: 89
Study 16309769 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 53)
Number of subjects: 89
Study 15266219 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg granisetron
Number of subjects: 90
Study 15266219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 90
Study 15266219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11677359 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (reduced in fats, emphasizes fruits, vegetables, and low-fat dairy products)
Number of subjects: 459
Study 11677359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (rich in fruits and vegetables, resembles control diet)
Number of subjects: 459
Study 11677359 — intervention group
Group type: COMPARATOR
Intervention: Control diet (similar to typical American intake)
Number of subjects: 459
Study 9882029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 48
Study 9882029 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PT)
Number of subjects: 48
Study 8154035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 800 mg orally or 400 mg i.v. q.i.d. for 12 weeks after transplantation or 6 weeks after any antirejection therapy
Number of subjects: 311
Study 8154035 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir (GCV) 5 mg/kg/12 hr i.v. for 7 days after transplant or after any antirejection therapy plus human immune globulin (HIg) 100 mg/kg i.v. administered on days 1, 4, and 7 after transplant or after any antirejection therapy
Number of subjects: 311
Study 3138628 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 100
Study 3138628 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study 29221717 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined with therapeutic lifestyle changes (TLC)
Number of subjects: 64
Study 29221717 — intervention group
Group type: COMPARATOR
Intervention: TLC alone
Number of subjects: 64
Study 26817789 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 63
Study 26817789 — intervention group
Group type: EXPERIMENTAL
Intervention: Template
Number of subjects: 63
Study 26817789 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aid (Control)
Number of subjects: 63
Study 25534864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of intravenous and topical tranexamic acid (TXA)
Number of subjects: 120
Study 25534864 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 120
Study 25534864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 120
Study 23064795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-positive SLN
Number of subjects: 509
Study 20647171 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155U-195U)
Number of subjects: 705
Study 20647171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 18249210 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-fat diet (25%)
Number of subjects: 14
Study 18249210 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (60%)
Number of subjects: 14
Study 18249210 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (10%)
Number of subjects: 14
Study 16801182 — intervention group
Group type: EXPERIMENTAL
Intervention: GosFos (1 g/100 mL)
Number of subjects: 20
Study 14696738 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm F
Number of subjects: 9
Study 14696738 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal toothpaste programme
Number of subjects: 9
Study 14696738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no toothpaste)
Number of subjects: 9
Study 10995002 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (L-asparaginase and intermediate-dose methotrexate)
Number of subjects: 1354
Study 10995002 — intervention group
Group type: COMPARATOR
Intervention: Regimen C (cytarabine and intermediate-dose methotrexate)
Number of subjects: 1354
Study 10995002 — intervention group
Group type: COMPARATOR
Intervention: Regimen C
Number of subjects: 1354
Study 10995002 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 1354
Study 10995002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 1354
Study 8810562 — intervention group
Group type: EXPERIMENTAL
Intervention: MLPA test for detection of anti-PGL-1 antibodies
Number of subjects: 0
Study 8810562 — intervention group
Group type: COMPARATOR
Intervention: Slit skin smear method
Number of subjects: 0
Study 8403676 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and implantation of gentamicin‐polymethylmethacrylate (PMMA) beads
Number of subjects: 28
Study 8403676 — intervention group
Group type: COMPARATOR
Intervention: Debridement and conventional parenteral systemic antibiotic therapy
Number of subjects: 28
Study 3527946 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (400 mg 17-1A immunoglobulin, single dose, intravenous)
Number of subjects: 16
Study 3527946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of monoclonal antibody and F.A.M. chemotherapy (5-fluorouracil, adriamycin, mitomycin)
Number of subjects: 16
Study 3527946 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (after 8-week cycle of F.A.M. chemotherapy)
Number of subjects: 16
Study 3527946 — intervention group
Group type: COMPARATOR
Intervention: F.A.M. chemotherapy
Number of subjects: 16
Study 29796742 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting suture using the septum stitch device
Number of subjects: 23
Study 29796742 — intervention group
Group type: COMPARATOR
Intervention: Nasal silicone splint method
Number of subjects: 23
Study 28076254 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 61
Study 28076254 — intervention group
Group type: COMPARATOR
Intervention: Overall patient-centeredness
Number of subjects: 61
Study 24618153 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Number of subjects: 1212
Study 24618153 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by eprirubicin/docetaxel (T-ET)
Number of subjects: 1212
Study 24618153 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 1212
Study 24618153 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy arm (T-ET)
Number of subjects: 1212
Study 24026296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (UG) technique
Number of subjects: 118
Study 24026296 — intervention group
Group type: COMPARATOR
Intervention: Landmark (LM) technique
Number of subjects: 118
Study 24026296 — intervention group
Group type: COMPARATOR
Intervention: Quick-look ultrasound with skin mark (UM) technique
Number of subjects: 118
Study 20799126 — intervention group
Group type: COMPARATOR
Intervention: Hypnosis (year-long weekly group intervention)
Number of subjects: 2
Study 20799126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 2
Study 18855808 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Families intervention (treatment-as-usual plus intervention)
Number of subjects: 177
Study 18855808 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control condition)
Number of subjects: 177
Study 17407944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimage-based navigation system
Number of subjects: 55
Study 17407944 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 55
Study 12597931 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2 mg administered intravenously 5 minutes before ESWL)
Number of subjects: 98
Study 12597931 — intervention group
Group type: EXPERIMENTAL
Intervention: Music chosen by the patients listened to with a headset during treatment
Number of subjects: 98
Study 11291604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir pre-emptive treatment
Number of subjects: 208
Study 11291604 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte serum (ATG)
Number of subjects: 208
Study 11291604 — intervention group
Group type: COMPARATOR
Intervention: None (control group lacking ATG)
Number of subjects: 208
Study 11291604 — intervention group
Group type: COMPARATOR
Intervention: None (control group of blood/platelet donors)
Number of subjects: 208
Study 9238868 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean (ID2)
Number of subjects: 52
Study 9238868 — intervention group
Group type: COMPARATOR
Intervention: Manual floss
Number of subjects: 52
Study 1482267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (N = 146)
Number of subjects: 316
Study 1482267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 170)
Number of subjects: 316
Study 6742647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol (chenodeoxycholic acid)
Number of subjects: 916
Study 6742647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 29781350 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line ethics education module
Number of subjects: 33
Study 30101524 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for owners on best practices to reduce workplace chemical exposures
Number of subjects: 200
Study 30101524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 200
Study 27433356 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending college
Number of subjects: 296
Study 27433356 — intervention group
Group type: EXPERIMENTAL
Intervention: More lymph nodes removed
Number of subjects: 296
Study 27433356 — intervention group
Group type: EXPERIMENTAL
Intervention: >25% BCRL care adherence
Number of subjects: 296
Study 27433356 — intervention group
Group type: EXPERIMENTAL
Intervention: Years since treatment
Number of subjects: 296
Study 27433356 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 296
Study 27433356 — intervention group
Group type: COMPARATOR
Intervention: BMI
Number of subjects: 296
Study 25275218 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost (80 μg twice a day orally)
Number of subjects: 14
Study 25275218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22510238 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg/day plus vardenafil 10 mg/day
Number of subjects: 60
Study 22510238 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin 0.4 mg/day
Number of subjects: 60
Study 21095265 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 months of clopidogrel therapy
Number of subjects: 1700
Study 21095265 — intervention group
Group type: COMPARATOR
Intervention: 6 months of clopidogrel therapy
Number of subjects: 1700
Study 18646528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (16.7 mg/d)
Number of subjects: 300
Study 18646528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (8.4 mg/d)
Number of subjects: 300
Study 18646528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (5.6 mg/d)
Number of subjects: 300
Study 18646528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC 300 mg/d) + Vitamin E (VE 200 mg/d) + beta-carotene (0.0 mg/d)
Number of subjects: 300
Study 18646528 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (VE 5 mg/d)
Number of subjects: 300
Study 15795365 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% oxygen
Number of subjects: 36
Study 15795365 — intervention group
Group type: COMPARATOR
Intervention: Breathing 21% oxygen
Number of subjects: 36
Study 12486649 — intervention group
Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer (250 mL, 500 mL, or 750 mL)
Number of subjects: 60
Study 12486649 — intervention group
Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer (750 mL)
Number of subjects: 60
Study 12486649 — intervention group
Group type: EXPERIMENTAL
Intervention: hemoglobin raffimer
Number of subjects: 60
Study 12486649 — intervention group
Group type: COMPARATOR
Intervention: 6% hetastarch (control)
Number of subjects: 60
Study 10367952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta 50 U/dose
Number of subjects: 520
Study 10367952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta 100 U/dose
Number of subjects: 520
Study 10367952 — intervention group
Group type: COMPARATOR
Intervention: Havrix 1440 U/dose
Number of subjects: 520
Study 10367952 — intervention group
Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 520
Study 10367952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta and Havrix
Number of subjects: 520
Study 10367952 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta
Number of subjects: 520
Study 9454115 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy patients
Number of subjects: 110
Study 9454115 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=30)
Number of subjects: 110
Study 2350052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent endotracheal anesthesia with neuroleptanalgesia and cardiopulmonary bypass, postoperative analgesia with non-narcotic and narcotic analgesics
Number of subjects: 60
Study 2350052 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia into upper chest segments with trimecaine + adrenaline and low morphine doses
Number of subjects: 60
Study 789027 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (Mucodyne)
Number of subjects: 82
Study 31761527 — intervention group
Group type: EXPERIMENTAL
Intervention: Received depression help-seeking message once
Number of subjects: 7017
Study 31761527 — intervention group
Group type: EXPERIMENTAL
Intervention: Received depression help-seeking message twice
Number of subjects: 7017
Study 31761527 — intervention group
Group type: COMPARATOR
Intervention: Never received depression help-seeking message
Number of subjects: 7017
Study 31761527 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to the message
Number of subjects: 7017
Study 30869025 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR using species-specific 18S rRNA primers for the Entamoeba complex
Number of subjects: 1383
Study 30869025 — intervention group
Group type: COMPARATOR
Intervention: Microscopic stool examination
Number of subjects: 1383
Study 28115837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi qigong (n=24)
Number of subjects: 48
Study 28115837 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (n=24)
Number of subjects: 48
Study 26394045 — intervention group
Group type: COMPARATOR
Intervention: PBA+vitD3
Number of subjects: 288
Study 26394045 — intervention group
Group type: COMPARATOR
Intervention: vitD3
Number of subjects: 288
Study 26394045 — intervention group
Group type: COMPARATOR
Intervention: PBA
Number of subjects: 288
Study 23485730 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive agility and trunk stabilization rehabilitation program
Number of subjects: 31
Study 23485730 — intervention group
Group type: COMPARATOR
Intervention: Progressive running and eccentric strengthening rehabilitation program
Number of subjects: 31
Study 23485730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rehabilitation programs
Number of subjects: 31
Study 21871779 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P seminars
Number of subjects: 53
Study 21871779 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 53
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment entry within four months
Number of subjects: 120
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drug use
Number of subjects: 120
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 120
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 120
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use moderation
Number of subjects: 120
Study 19579092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin use among non-treatment entrants
Number of subjects: 120
Study 17027823 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise training (900 kcal/week, 3-5 sessions per week, for 12 weeks)
Number of subjects: 103
Study 17027823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity cycling exercise training (900 kcal/week, 3-5 sessions per week, for 12 weeks)
Number of subjects: 103
Study 17027823 — intervention group
Group type: COMPARATOR
Intervention: Moderate and vigorous physical activity
Number of subjects: 103